drugset / Trial / NCT02231658
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
RandomizedParallel-groupSingle-blindTreatment
Summary
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
Timeline
- Start
- 2015-07-16
- Primary completion
- 2018-07-23
- Completion
- 2018-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |
| Subject | Lixisenatide | Peptide | 20 ug | Subcutaneous |